Febit has announced that an updated version of the company's miRBase 14 Geniom Biochip with 58 additional new sequences is now available for cancer research.
The Geniom Biochip contains 58 new discovered sequences in addition to all of the Homo sapiens microRNAs (miRNA) from miRBase version 14.
The new miRNA sequences were found by deep sequencing in a miRNA discover study performed on an Applied Biosystems Solid 3 sequencing system.
All 58 miRNAs have been validated using the ABI Taqman miRNA qRT-PCR assay and are now available for further studies using Febit's micro-array technology for miRNA profiling.
Several studies investigating the role of miRNAs showed evidence for their influence in cell development processes.
Recently, promising biomarkers for the future diagnosis and differentiation of ling cancer and multiple sclerosis have been published in BMC Cancer and PLoS One.
The results demonstrated that miRNA biomarkers reliably distinguish between affected and healthy individuals by analysing whole blood samples.
Each miRNA is part of a meaningful pattern giving information about individual regulatory processes.
Therefore each miRNA of the Geniom Biochip - from either miRBase 14 or the Solid sequencing studies - will be of high scientific impact and can be a potential biomarker candidate or therapeutically relevant molecules.
